Scilex (NASDAQ:SCLX) and Arcellx (NASDAQ:ACLX) Head to Head Contrast

Arcellx (NASDAQ:ACLX) and Scilex (NASDAQ:SCLX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Valuation and Earnings

This table compares Arcellx and Scilex’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcellx	$144.75 million	26.34	-$70.69 million	($1.03)	-69.17
Scilex	$50.83 million	3.71	-$114.33 million	($1.31)	-0.79

Arcellx has higher revenue and earnings than Scilex. Arcellx is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

96.0% of Arcellx shares are owned by institutional investors. Comparatively, 69.7% of Scilex shares are owned by institutional investors. 6.2% of Arcellx shares are owned by insiders. Comparatively, 8.7% of Scilex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Arcellx and Scilex’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Arcellx	-37.23%	-12.42%	-7.30%
Scilex	-233.88%	N/A	-111.82%

Analyst Ratings

This is a summary of current recommendations and price targets for Arcellx and Scilex, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcellx	0	0	14	1	3.07
Scilex	0	0	3	0	3.00

Arcellx presently has a consensus target price of $78.00, suggesting a potential upside of 9.47%. Scilex has a consensus target price of $8.00, suggesting a potential upside of 669.23%. Given Scilex’s higher probable upside, analysts clearly believe Scilex is more favorable than Arcellx.

Risk & Volatility

Arcellx has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500. Comparatively, Scilex has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500.

Summary

Arcellx beats Scilex on 10 of the 15 factors compared between the two stocks.

About Arcellx

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

About Scilex

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.